http://www.lsis.com/goto/r101/rss 2010-06-23T11:11:00+01:00 text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v101/%3B%97f%FB%10%7D%7Dr Highlighted Links Bausch + Lomb ROCHESTER, NY-(Marketwire - June 20, 2010) - Bausch + Lomb, the global eye health company, has appointed Rodney (Rod) W. Unsworth as president, Asia-Pacific, effective July 1. "Rod has an extensive and successful record of driving transformational change in global health care companies, with a particular focus on Asia-Pacific," said Brent Saunders, chief executive officer, Bausch + Lomb. "His counsel and leadership will be extremely valuable as we work to build B+L into a high-performance competitor in Asia and worldwide." "There are exciting opportunities for B+L in this dynamic growth region," said Mr. Unsworth. "I look forward to working with our teams (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FB%11t%7Dx WELLESLEY, Mass.-(BUSINESS WIRE)-NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body s ability to deliver oxygen to diseased tissues, today announced that John A. Hey, Ph.D., has been appointed Senior Vice President of Preclinical and Early Development. In this role, Dr. Hey will be responsible for the drug discovery and preclinical drug development activities for NormOxys platform of novel oxyren compounds, as well as all preclinical research. Dr. Hey will work closely with the NormOxys management team to support the advancement of clinical lead OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin, which is (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FB%11t%7C%7C WHITEHOUSE STATION, N.J. & REDWOOD CITY, Calif.-(BUSINESS WIRE)-Merck and Codexis, Inc. (NASDAQ:CDXS) today announced that they have jointly been awarded the annual Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) for the development of a novel biocatalytic method for the synthesis of sitagliptin. In addition, a paper co-authored by Merck and Codexis scientists and published online June 17 in the peer-reviewed journal Science, details how an enzyme was systematically customized using Codexis technology to perform the key chemical step in the sitagliptin synthesis process. This process showed improved efficiency and significantly decreased (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97f%FB%11zvy ROCHESTER, NY-(Marketwire - June 20, 2010) - Highlighted Links Bausch + Lomb Bausch + Lomb, the global eye health company, has appointed Rodney (Rod) W. Unsworth as president, Asia-Pacific, effective July 1. "Rod has an extensive and successful record of driving transformational change in global health care companies, with a particular focus on Asia-Pacific," said Brent Saunders, chief executive officer, Bausch + Lomb. "His counsel and leadership will be extremely valuable as we work to build B+L into a high-performance competitor in Asia and worldwide." "There are exciting opportunities for B+L in this dynamic growth region," said Mr. Unsworth. "I look forward to working with our teams (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97f%FC%1D%7Dyx Separation of chiral primary amino compounds was efficiently achieved under reversed-phase high performance liquid chromatography (RP-HPLC) conditions using a mixture of non-chiral crown ether (18-crown-6) and dimethyl-beta-cyclodextrin (DM-beta-CD) in the mobile phase. Under these conditions, the amino group of the chiral compound was protonated in a low pH mobile phase, and then interacted with 18-crown-6 and DM-beta-CD to form a sandwiched complex [18-crown-6+amine+CD]. Enantiomers of the compound in the sandwiched complex were separated with good enantioselectivity. Formation of the sandwiched complex among the chiral compound and additives in the mobile phase is a key step of the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FC%12%7E%7Ex CAMBRIDGE, Mass.-(BUSINESS WIRE)-Genzyme Corporation (NASDAQ: GENZ) announced that all 10 members of its board of directors were re-elected at its annual meeting of shareholders today. Shareholders also approved all of the company s proposals, including those regarding equity plans and the employee stock purchase program. In addition, the board voted to appoint three new directors. Genzyme s board appointed Dennis M. Fenton, Ph.D., a highly regarded industry leader in manufacturing and 25-year veteran of Amgen Inc., as a director. The appointment fulfills the commitment made by Genzyme as part of its agreement with Relational Investors, LLC to nominate an independent director recommended (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FC%12%7Dws DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f241be/merck_co_inc) has announced the addition of the "Merck & Co., Inc. - SWOT Analysis" company profile to their offering. Merck & Co., Inc. - SWOT Analysis The Merck & Co., Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. Merck & Co., Inc. - SWOT Analysis examines the companys key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Merck & Co. is one of the research driven Big Pharma companies. The company is engaged in research, manufacturing and marketing of drugs and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FC%12%7D%7By ROME-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR). I look forward to the next phase of clinical development that will provide additional understanding of the efficacy and safety profile of this antibody. The 16-week Phase 2a study evaluated the safety and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97f%FD%1Ct%7Dr ROME-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE:BMY - News) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR). The 16-week Phase 2a study evaluated the safety and efficacy of BMS-945429/ALD518 in 132 patients with RA inadequately controlled with methotrexate. Patients were randomized to receive intravenous (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97f%FD%1C%7Bwz June 17 (Bloomberg) - Merck & Co. plans to cut about 800 jobs in France, or 20 percent of its workforce in the country, following its purchase of Schering-Plough last year, French daily La Tribune reported, citing management and unions. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97f%FD%1C%7Bv%7E Schizophrenia played a prominent role at this year's American Psychiatric Association Annual Meeting due to the prevailing high level of unmet need. Merck & Co and Dainippon Sumitomo presented data for new drugs which Datamonitor believes represent important additions to the current treatment portfolio. Elsewhere, an interesting lecture predicted a future of personalized schizophrenia treatments. Dainippon Sumitomo: lurasidone Phase III data validates potential This year's American Psychiatric Association meeting (APA 2010) provided an opportunity for attendees to assess the potential of Dainippon Sumitomo's lurasidone ahead of its expected approval in late 2010. At the meeting, the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97f%FD%1C%7B%7Cr FRAMINGHAM, Mass., Jun 16, 2010 (BUSINESS WIRE) - GTC Biotherapeutics, Inc. announced the closing of a new $7 million secured convertible debt financing by its strategic partner, LFB Biotechnologies SAS ("LFB" Les Ulis, France), in connection with a restructuring of GTC's operations which will result in a downsizing of approximately 30 full-time positions at its headquarters and an additional 20 positions at its farm facility. In addition, Geoffrey Cox and several other members of the current senior management team will be leaving GTC. Board member William Heiden has been named Chairman, CEO and President. The convertible debt will mature on June 15, 2013 and will bear interest at an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97f%FD%1C%7F%7C%7F CONTEXT: Osteoarthritis (OA) is a common cause of chronic pain, particularly in the older population. Modern approaches to the management of OA pain recommend tailoring treatment to the individual. This study examines treatment options for OA pain in the form of low-dose transdermal and sublingual opioid analgesia. OBJECTIVES: The aims of this trial were to compare the efficacy and tolerability of seven-day, low-dose transdermal buprenorphine patches (BuTrans(R), Napp Pharmaceuticals Limited UK) with sublingual buprenorphine (Temgesic(R), Schering-Plough Limited UK) in patients with moderate to severe pain caused by OA of the hip(s) and/or knee(s), and to establish analgesic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FD%11%7Exs WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding ¢ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today ( œUppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced ), UMC s new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug Dictionary Enhanced is the world s most comprehensive dictionary of medicinal product information and the de facto standard for coding (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v101/%3B%97f%FE%12xz%7B ScienceDaily (June 9, 2010) Heart attacks declined by 24 percent within a large, ethnically diverse, community-based population since 2000, and the relative incidence of serious heart attacks that do permanent damage declined by 62 percent, according to a Kaiser Permanente Division of Research study in the current issue of the New England Journal of Medicine. See Also: Health & Medicine Heart Disease Stroke Prevention Vioxx Science & Society Public Health Social Issues Bioethics Reference Ischaemic heart disease Coronary heart disease Electrocardiogram Panic attack The reductions in death after heart attack are driven in part by the decline in incidence of more severe heart attacks known (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FE%13uvs SAN ANTONIO-(BUSINESS WIRE)-Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FE%13uv%7E GERMANTOWN, Md.-(BUSINESS WIRE)-Psyadon Pharmaceuticals, Inc. announces today the opening of a clinical research site at the University of California at San Diego headed by Dr. William Nyhan. He joins Dr. Hyder Jinnah at Emory University to study the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with Lesch-Nyhan Disease (LND). Since ecopipam works selectively on the dopaminergic system, I believe it has the potential to significantly impact the disease, and I am very excited to participate in the clinical trial. Dr. Nyhan (in collaboration with Dr. Michael Lesch) was the first to definitively report this disease (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97f%FE%11u%7B%7C Demonstration of the absence of neurovirulent properties of reassortant viruses contained in live attenuated influenza vaccine (LAIV) is a regulatory requirement. A mouse model was used to detect neurovirulent properties of the cold-adapted, temperature-sensitive and attenuated influenza master donor viruses (MDVs) A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortant influenza viruses. A/NWS/33 (H1N1), which is known to be neurovirulent in mice, was used as a positive control. Under conditions where the positive control virus induced symptoms of disease and showed viral replication in the upper respiratory tract as well as in the brain, replication of the influenza master (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97f%FF%13uz%7E CAMBRIDGE, Mass.-(BUSINESS WIRE)-AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck). In addition, AVEO announced the presentation of results of a Phase 1 safety and tolerability trial of SCH 900105, an investigational antibody targeting hepatocyte growth factor/scatter (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FF%13t%7B%7F CAMBRIDGE, Mass.-(BUSINESS WIRE)-AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck). In addition, AVEO announced the presentation of results of a Phase 1 safety and tolerability trial of SCH 900105, an investigational antibody targeting hepatocyte growth factor/scatter (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97f%FF%17ywr Highly pathogenic avian influenza A viruses of the H5N1 subtype continue to circulate in poultry and zoonotic transmissions are reported frequently. Since a pandemic caused by these highly pathogenic viruses is still feared, there is interest in the development of influenza A/H5N1 virus vaccines that can protect humans against infection, preferably after a single vaccination with a low dose of antigen. Here we describe the induction of humoral and cellular immune responses in ferrets after vaccination with a cell-culture derived whole inactivated influenza A virus vaccine in combination with the novel adjuvant CoVaccine HT(TM). The addition of CoVaccine HT(TM) to the influenza A virus (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FF%15u%7Ey CHICAGO-(BUSINESS WIRE)-Today, Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. The global network comprises leading cancer research centers who will partner with Merck to speed the development of innovative treatments for a range of cancers. A first-in-man trial of poly (ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with anti-tumor activity in BRCA-deficient and sporadic ovarian cancers. Cancer is a diverse group of diseases that accounts for 7.4 million deaths (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97f%FF%15tv%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f8bc26/option_and_evaluat) has announced the addition of the "Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition" report to their offering. Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v101/%3B%97g%F6%12zzs NEW YORK, NY-(Marketwire - June 2, 2010) - ExL Pharma's 6th Public Relations and Communications Summit for Pharmaceutical, Biotech and Medical Technology Communicators is taking place this summer at the Pfizer World Headquarters on July 26-27, 2010 in New York, New York. This leading event, which is well attended by communications professionals in pharmaceutical, biotech and medical device companies, features two full days of expert-led presentations, networking opportunities, and interactive sessions. Attendees will gain concrete strategies for success in the marketplace and improved patient outcomes through strengthened communications. *Register before June 11, 2010 to save $200 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%F6%12%7Fwy CHICAGO-(BUSINESS WIRE)-Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy. The regimen containing 150 mg fosaprepitant dimeglumine was not inferior to the regimen with oral aprepitant. Results of the study, known as EASE-017, will be presented on June 8th at the 2010 American (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97g%F6%12%7Dw%7C Can Vet J. |-| Osborne D. |-| This article is provided as part of the CVMA Business Management Program, which is co-sponsored by Hill's Pet Nutrition Canada Inc., Petsecure Insurance, Intervet Schering-Plough Animal Health, and Scotiabank. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v101/%3B%97g%F6%10%7Fwz Novartis announced that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy The comparator arm in the trial was Doxil/Caelyx (pegylated liposomal doxorubicin). Investigators involved in the study and regulatory agencies have been notified of the trial outcome. No new or unexpected serious adverse events in the patupilone arm were identified in the trial. Novartis does not plan to proceed with regulatory filings based on these data. Study details The Phase III study, conducted in approximately 168 sites in 22 countries, was an open label, active (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97g%F6%14%7E%7Br DURHAM, NC, and LIEGE, BELGIUM - May 31, 2010, 8:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, today announced that its Annual General Shareholders' Meeting (AGM) held on 28 May, 2010, approved the appointment of Ms. Hilde Windels, Mr. Edward L. Erickson, and Mr. Mark Myslinski to the Board of Directors, as well as all other agenda items of the AGM. The appointment of the new directors is effective immediately for a period until the 2013 AGM. Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said: "I am delighted that our shareholders have appointed these directors who bring a wealth of relevant (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%F7%10%7Dw%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2ea526/expanding_a_produc) has announced the addition of the "Expanding a Product Portfolio Without Cannibalizing an Established Brand" report to their offering. Expanding a Product Portfolio Without Cannibalizing an Established Brand Managing multiple products for the same indication is a complex balancing act for bio-pharmaceutical companies today especially those that want to prevent one of their brands from gaining market share at the expense of another. Maximizing the potential of each product requires well-crafted marketing strategies and smart resource allocation plans. Marketers have to make (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97g%F7%14x%7D%7D DURHAM, NC, and LIEGE, BELGIUM - May 27, 2010,10:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today that its Belgium based clinical diagnostics service laboratory has received the important ISO 9001:2008 certification from Lloyds Register Quality Assurance Ltd. ISO's internationally recognized standard confirms that Oncomethylome Sciences' Quality Management System consistently meets customer and regulatory requirements for research, design, assay development and clinical molecular diagnostic service testing. "The ISO certification for our quality management system constitutes an essential (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%F7%14%7D%7Ds DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6a4d4a/the_top_10_pharmac) has announced the addition of the "The Top 10 Pharmaceutical Companies in Latin America: Growth Performance, Strategies and SWOT Analysis" report to their offering. The Top 10 Pharmaceutical Companies in Latin America: Growth Performance, Strategies and SWOT Analysis The leading pharmaceutical companies in Latin America comprise multinational companies and domestic players. Brazil, Mexico, Venezuela and Argentina remained the major markets in Latin America with a market share of around 90%. This report provides an insight into the current state of the Latin American (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%F7%14%7D%7D%7E WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-At their meeting today, the Board of Directors of Merck & Co., Inc. declared a quarterly dividend of $0.38 per share on the company s common stock for the third quarter of 2010. Payment will be made on July 8, 2010 to common stockholders of record at the close of business on June 15, 2010. The Board of Directors today also declared a quarterly dividend of $3.67 per share on the company s mandatory convertible preferred stock for the third quarter of 2010. Payment will be made on Aug. 13, 2010 to preferred stockholders of record at the close of business on Aug. 2, 2010. About Merck Today's Merck is working to help the world be well. Through our (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%F7%14%7D%7Ez NEW YORK-(BUSINESS WIRE)-Amid the national debate on healthcare industry reform, the Ethisphere Institute, a leading international think-tank dedicated to the creation, advancement and sharing of best practices in business ethics and compliance, today announced that the latest issue of Ethisphere Magazine will focus on ethical issues in the healthcare industry. Like all issues of Ethisphere Magazine, the Q1 edition, dubbed the œHealthcare Issue,  covers the most recent ethics and compliance activities in the business world, with this quarter s issue focusing particularly on ethical issues and practices across various sectors of the healthcare industry. Alan Yuspeh is extremely (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97g%F8%1D%7C%7Ds Associated Press - Merck & Co. is enjoying a spurt of new drug launches, partly due to its $41 billion November acquisition of New Jersey neighbor Schering-Plough Corp. Some have been on the market in the United States for a while, including blockbuster diabetes medicine Januvia, and are now being launched in other countries. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%F8%12zv%7D SAN DIEGO-(BUSINESS WIRE)-NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT technology, today announced the expansion of its senior business development team within NexMed (U.S.A.), with the appointments of Linda Smibert as Vice President of Business Development and Mark S. Wilson as Vice-President of Technology Development. Both executives will report to Vivian Liu, the Company s Executive Vice-President. In her new position, effective May 26, 2010, Ms. Smibert will spearhead the out-licensing of NexMed s pre-clinical and clinical product pipeline. Prior to joining the Company, Ms. Smibert served for eight years as Senior Director and Director (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97g%F8%11%7Bxr Fresh and dried raspberries prepared by freeze drying (FD), microwave-vacuum (MIVAC), hot-air drying (HAD), and a combination of hot-air drying and microwave-vacuum (HAD/MIVAC) drying methods were evaluated for polyphenol retention, total polyphenol and anthocyanin contents, total antioxidant capacity, and antiadipogenic activity (the inhibition of fat cell development). Ellagic acid and quercetin were present in the largest concentrations in fresh and dehydrated raspberries. Dehydration led to a loss of polyphenols and anthocyanins and antioxidant capacity. Polyphenols (aglycone form) were retained in the greatest amount: 20% (freeze dried) to 30% (HAD/MIVAC) (fresh = 100%). A total of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97g%F8%16u%7E%7F The instantaneous rate of population increase was used to assess the ability of attractive targets coated with permethrin to control stable fly populations on 3 dairy farms in south central Ontario, Canada. Two attractive targets were deployed over 10 wk in 2001 at each of 6 dairy farms. Three farms were outfitted with 2 untreated targets and 3 were outfitted with 2 targets treated with permethrin [Ectiban-impregnated Coroplast (Ectiban: Schering-Plough Canada Inc., Pointe-Claire, Québec, Canada; Coroplast: Great Pacific Enterprises Inc., Granby, Québec, Canada)]. Population growth rate was measured in terms of degree-days above a 10 degrees C developmental threshold (r(DD10). The (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97g%F8%17y%7Bs Cambridge, UK, 25th May 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that Dr Ismail Kola has joined its Board of Directors. Dr Kola is currently Executive Vice President of UCB S.A in Belgium where he was appointed in November 2009 and also holds the title President, New Medicines. Dr Kola joined UCB from Schering Plough Corporation where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine at Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, and Chief Scientific Officer, Schering Plough Corporation. Prior to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97g%F9%1C%7B%7Es The objective of this phase 1, open-label, parallel, randomized study was to determine the effect of posaconazole on the pharmacokinetics of caspofungin and micafungin in 67 healthy subjects. Caspofungin (70 mg on day 1, 50 mg on days 2-14 once daily; 1-hour intravenous infusion) (cohort 1) or micafungin (150 mg once daily days 1-7; 1-hour IV infusion) (cohort 2) was administered alone or with posaconazole oral suspension 400 mg twice daily, on days 1 to 14 (cohort 1) or days 1 to 7 (cohort 2). Pharmacokinetic parameters, maximum plasma concentration (Cmax), steady-state area under the plasma concentration-time curve over the dosing interval (AUC[tau]), and time to Cmax (Tmax) were (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97g%F9%1Duv%7F The infliximab (Remicade(R); Schering-Plough, Kenilworth, NJ, USA) Risk Management Plan included the development, execution and tracking of an education programme directed towards prescribers of infliximab for patients with paediatric Crohn's disease (the Infliximab Paediatric Crohn's Disease Educational Plan). The programme content consisted of educational materials and communications aimed at educating prescribers on the risks associated with infliximab use. To evaluate the effectiveness of the risk minimization plan. Evaluation focused on two components: documentation of training of sponsors' personnel, and evaluation of awareness among prescribing physicians in European countries. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97g%F9%10%7D%7F%7C Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of renal insufficiency may receive vicriviroc, which is metabolized by cytochrome P450 (CYP) 3A4. The present study therefore examined the impact of renal insufficiency on the pharmacokinetics and safety of vicriviroc alone and in the presence of ritonavir, a strong CYP3A4 inhibitor. This study was an open-label, randomized, two-treatment crossover trial conducted in HIV-negative subjects with (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v101/%3B%97g%F9%17tvz NEW YORK, NY-(Marketwire - May 20, 2010) - Marketwire and ExL Pharma are proud to announce their partnership for the 6th Annual Public Relations and Communications Summit, taking place at the Pfizer World Headquarters in Manhattan on July 26-27, 2010. For the second year in a row, Marketwire is the official newswire of this leading meeting for communications professionals in pharmaceutical, biotechnology and medical device companies. Featuring more than forty-five speakers from top industry companies, this event will provide comprehensive presentations, panel discussions and opportunities for dialogue around issues that are most relevant to product, corporate and organizational (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%F9%17zx%7C MENLO PARK, Calif.-(BUSINESS WIRE)-Geron Corporation (Nasdaq: GERN) today announced the appointment of Hoyoung Huh, M.D., Ph.D. and Robert J. Spiegel, M.D., FACP to its board of directors. Dr. Huh and Dr. Spiegel are both highly qualified to make important contributions to our clinical development strategies and we are pleased to welcome them to the board. œGeron is pleased to add two additional directors with significant operating and product development experience as the company advances its clinical trials in oncology through Phase II and moves its cell therapies into the clinic,  said Alex Barkas, chairman of Geron s board of directors. œDr. Huh and Dr. Spiegel are both highly (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v101/%3B%97g%FA%12yxr In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer's disease (AD) affects patients with and without the apolipoprotein E µ4 gene (APOE µ4), a known genetic risk factor for the neurodegenerative disease, using a combination of cognitive and neuroanatomic measures. The study found that this gene influences the way the disease manifests, even at its mildest clinical stages. Study highlights include: - Patients with mild AD who carry the µ4 form of the APOE gene perform more poorly on memory tests and have more prominent abnormalities in brain regions critical for memory, compared with patients without this gene (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%FA%12xvy DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8fac3e/acute_coronary_syn) has announced the addition of the "Acute Coronary Syndrome - Global Strategic Business Report" report to their offering. Acute Coronary Syndrome - Global Strategic Business Report This report analyzes the global market for Acute Coronary Syndrome Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 60 companies including Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%FA%12%7Fyy EXTON, Pa.-(BUSINESS WIRE)-Morphotek, Inc. today announced the appointment of Joye L. Bramble, Ph.D. as Vice President, Pilot Plant Operations. In this role, Dr. Bramble will have full responsibility for the management and operation of Morphotek s new pilot manufacturing plant, which will produce biologics to support the company s early-stage clinical trials. The company broke ground for the new $80 million facility in March 2010 and expects operations to begin by fall 2012. Morphotek is a subsidiary of Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd. We are extremely pleased to welcome Dr. Bramble to the Morphotek management team With more than two decades of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v101/%3B%97g%FA%16%7Dzx Antagonists of the 5-HT(6) receptor have been shown to improve cognitive function in a wide range of animal models and as such may prove to be attractive agents for the symptomatic treatment of cognitive disorders such as Alzheimer's disease (AD) and schizophrenia. We report herein the identification and SAR around N-(2-aminoalkyl)-1-(arylsulfonyl)indoline-3-carboxamides-a novel chemotype of 5-HT(6) antagonists. |-| Bioorg Med Chem Lett. |-| Reid M, Carlyle I, Caulfield WL, Clarkson TR, Cusick F, Epemolu O, Gilfillan R, Goodwin R, Jaap D, O'Donnell EC, Presland J, Rankovic Z, Spinks D, Spinks G, Thomson AM, Thomson F, Strain J, Wishart G. |-| Department of Chemistry, Schering-Plough (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v101/%3B%97g%FB%1C%7Czr DENVER-(BUSINESS WIRE)-In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) (NYSE: MRK) and Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) to treat atrial fibrillation, showed that BRINAVESS was superior to amiodarone injection, in converting patients' heart rate from atrial fibrillation (AF) to sinus rhythm (SR) within 90 minutes of the start of administration. The results of the study were presented today during a late-breaking clinical trials session at Heart Rhythm 2010, the annual meeting of the Heart Rhythm Society. Atrial fibrillation is the most common (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97g%FB%13%7Eyr Forbes - At Merck's annual meeting earlier this week, much of the focus was on two clot-preventing drugs the company is developing: vorapaxar, which it acquired as part of its merger with Schering-Plough, and betrixiban, which Merck licensed from Portola, a smaller drug firm. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v101/%3B%97g%FB%13%7Ey%7E In the study, called AVRO (Active-Controlled, Multi-Center Study of Vernakalant Injection versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation), 51.7 percent (n=116) of patients on BRINAVESS converted from atrial fibrillation to normal sinus rhythm within 90 minutes, versus 5.2 percent (n=116) in the amiodarone group (p 2 events in either group) were dysgeusia (bad taste in mouth) which occurred in 6.9 percent of patients on BRINAVESS (n=116) versus zero on amiodarone (n=116); cough (3.4 percent on BRINAVESS vs. 1.7 percent on amiodarone); sneezing (3.4 percent on BRINAVESS vs. zero on amiodarone); atrial fibrillation (3.4 percent on BRINAVESS vs. zero on amiodarone); nausea (…)